AU769387B2 - Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties - Google Patents

Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties Download PDF

Info

Publication number
AU769387B2
AU769387B2 AU21911/01A AU2191101A AU769387B2 AU 769387 B2 AU769387 B2 AU 769387B2 AU 21911/01 A AU21911/01 A AU 21911/01A AU 2191101 A AU2191101 A AU 2191101A AU 769387 B2 AU769387 B2 AU 769387B2
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU21911/01A
Other languages
English (en)
Other versions
AU2191101A (en
Inventor
Ronnie Maxwell Lawrence
Alan Millar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2191101A publication Critical patent/AU2191101A/en
Application granted granted Critical
Publication of AU769387B2 publication Critical patent/AU769387B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
AU21911/01A 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties Ceased AU769387B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9929297 1999-12-11
GBGB9929297.1A GB9929297D0 (en) 1999-12-11 1999-12-11 Process
PCT/GB2000/004697 WO2001042195A1 (en) 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Publications (2)

Publication Number Publication Date
AU2191101A AU2191101A (en) 2001-06-18
AU769387B2 true AU769387B2 (en) 2004-01-22

Family

ID=10866125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21911/01A Ceased AU769387B2 (en) 1999-12-11 2000-12-08 Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties

Country Status (23)

Country Link
US (1) US6548523B2 (enExample)
EP (1) EP1235788B1 (enExample)
JP (1) JP4903964B2 (enExample)
KR (1) KR100683614B1 (enExample)
CN (1) CN1224609C (enExample)
AT (1) ATE292110T1 (enExample)
AU (1) AU769387B2 (enExample)
BR (1) BRPI0016187B1 (enExample)
CA (1) CA2394117C (enExample)
CZ (1) CZ303143B6 (enExample)
DE (1) DE60019157T2 (enExample)
ES (1) ES2236020T3 (enExample)
GB (1) GB9929297D0 (enExample)
HK (1) HK1045988B (enExample)
HU (1) HU229043B1 (enExample)
IL (1) IL149585A0 (enExample)
NO (1) NO323239B1 (enExample)
NZ (1) NZ518795A (enExample)
PL (1) PL200540B1 (enExample)
PT (1) PT1235788E (enExample)
TR (1) TR200201528T2 (enExample)
WO (1) WO2001042195A1 (enExample)
ZA (1) ZA200204585B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230147A1 (de) * 2001-10-09 2004-01-15 Profos Ag Verfahren zur unspezifischen Anreicherung von Bakterienzellen
US7158049B2 (en) * 2003-03-24 2007-01-02 Schlumberger Technology Corporation Wireless communication circuit
US8213085B2 (en) * 2008-01-18 2012-07-03 Visera Technologies Company Limited Image sensor device with high photosensitivity
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
KR20150020160A (ko) 2012-02-09 2015-02-25 앨씨알엑스, 인크. 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
CA2969405A1 (en) 2014-12-03 2016-06-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1551260A (en) 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
JP2577222B2 (ja) * 1987-04-10 1997-01-29 興和株式会社 新規な置換アニリド誘導体
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
SK16282000A3 (sk) * 1998-05-01 2001-05-10 Abbott Laboratories Substituované beta-aminokyselinové inhibítory metionínaminopeptidázy-2
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
PL356483A1 (en) 2004-06-28
CN1409700A (zh) 2003-04-09
IL149585A0 (en) 2002-11-10
AU2191101A (en) 2001-06-18
NZ518795A (en) 2004-02-27
TR200201528T2 (tr) 2002-09-23
PL200540B1 (pl) 2009-01-30
DE60019157D1 (de) 2005-05-04
WO2001042195A1 (en) 2001-06-14
CZ303143B6 (cs) 2012-05-02
KR100683614B1 (ko) 2007-02-16
CZ20022017A3 (cs) 2003-01-15
NO20022758L (no) 2002-07-01
BRPI0016187B1 (pt) 2016-08-02
HUP0203640A2 (hu) 2003-02-28
ES2236020T3 (es) 2005-07-16
CN1224609C (zh) 2005-10-26
US6548523B2 (en) 2003-04-15
BR0016187A (pt) 2002-08-13
ZA200204585B (en) 2003-12-31
KR20020061636A (ko) 2002-07-24
ATE292110T1 (de) 2005-04-15
GB9929297D0 (en) 2000-02-02
CA2394117A1 (en) 2001-06-14
EP1235788A1 (en) 2002-09-04
HK1045988B (en) 2005-07-15
JP4903964B2 (ja) 2012-03-28
HU229043B1 (hu) 2013-07-29
DE60019157T2 (de) 2006-02-02
EP1235788B1 (en) 2005-03-30
PT1235788E (pt) 2005-08-31
HUP0203640A3 (en) 2003-08-28
US20020198220A1 (en) 2002-12-26
NO20022758D0 (no) 2002-06-10
HK1045988A1 (en) 2002-12-20
NO323239B1 (no) 2007-02-05
CA2394117C (en) 2011-10-04
JP2003516383A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
AU769387B2 (en) Process for the preparation of arylethanolamine derivatives having an anti-obesity and anti-diabetic properties
JP2003503317A (ja) 除草剤誘導体の製法
AU2024246814A1 (en) Cyclic amine derivative, and composition and use thereof
WO2008020532A1 (fr) Nouveau cristal de phosphate d'acide 5-aminolévulinique et son procédé de fabrication
SK50052004A3 (sk) Nová forma N-(trans-4-izopropylcyklohexylkarbonyl)-D-fenylalanínu
AU2002253815B2 (en) Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
CN101528673B (zh) 不对称铜络合物结晶的制造方法
WO2011091677A1 (zh) 阿利吉仑中间体3-氨基-2，2-二甲基丙酰胺的制备方法
CN109608407B (zh) 一种二苯并七元含氮杂环化合物的合成方法
CN1089757C (zh) 生产硝基氨基吡啶的方法
CN101346347B (zh) 氨基酸磷酸盐的制备方法
MXPA02005823A (en) Process for the preparation of arylethanolamine derivatives having an anti obesity and anti diabetic properties
CA2734896A1 (en) Therapeutic substituted pyrroles
CN103724352B (zh) 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法
TW200413281A (en) Process for preparing s-(2-aminoethyl)-2-methyl-l-cysteine
CN117342978A (zh) 一种胺的氰甲基化方法
CN101353345A (zh) 一种多胺与聚酰胺缀合物及其制备方法
JP2013100279A (ja) マンデル酸アミド誘導体の製造方法及びその中間体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)